RxDoctor Payments Data

Erin Birchenough, NP

Family · Watertown, NYNPI 1922394725

Payments from drug & device makers

$422in general payments, 2019–2025

Across 14 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$153
  • Kyowa Kirin, Inc.$83
  • Vifor Pharma, Inc.$62
  • Otsuka America Pharmaceutical, Inc.$39
  • GSK$39
  • Bayer$18
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$37990%
  • Education$4410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 55th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$193,890
Medicare patients
380
Services billed
8,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa50$42,571
VeltassaPatiromer Calcium Sorbitex27$40,554
Cinacalcet Hcl134$36,935
KerendiaFinerenone26$32,898
FarxigaDapagliflozin Propanediol29$24,501
JardianceEmpagliflozin16$19,433
EntrestoSacubitril/Valsartan30$16,752
Febuxostat62$11,065
TrulicityDulaglutide11$10,258
Potassium Citrate ErPotassium Citrate91$8,839
JanuviaSitagliptin Phosphate12$8,056
Potassium Chloride249$7,024
Calcitriol421$6,495
Breo ElliptaFluticasone/Vilanterol12$4,907
Torsemide167$4,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$18$32,89826 claims
AstraZenecaFarxiga$153$24,50129 claims
GSKBreo Ellipta$39$4,90712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,883 family providers in New York.

Other family in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →